Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population

References

• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of psoriasis and psoriatic arthritis in Italy-a systematic review. Curr Rheumatol Rep. 2018;20(7):43. doi:10.1007/s11926-018-0753-1
   PubMed Web of Science ®Google Scholar
• Armstrong AW. Psoriasis. JAMA Dermatol. 2017;153(9):956. doi:10.1001/jamadermatol.2017.2103
   PubMedGoogle Scholar
• Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54(4):685–704. doi:10.1016/j.jaad.2005.10.008
   PubMed Web of Science ®Google Scholar
• Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatol Clin. 2004;22(4):389–viii. doi:10.1016/j.det.2004.03.016
   PubMed Web of Science ®Google Scholar
• Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology. 2013;52(3):568–575. doi:10.1093/rheumatology/kes324
   PubMed Web of Science ®Google Scholar
• Li R, Sun J, Ren LM, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology. 2012;51(4):721–729. doi:10.1093/rheumatology/ker370
   PubMed Web of Science ®Google Scholar
• Carneiro JN, Paula AP, Martins GA. Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasília. An Bras Dermatol. 2012;87(4):539–544. doi:10.1590/s0365-05962012000400003
   PubMed Web of Science ®Google Scholar
• Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–740. doi:10.1136/annrheumdis-2012-201706
   PubMed Web of Science ®Google Scholar
• Zabotti A, Tinazzi I, Aydin SZ, McGonagle D. From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention. Curr Rheumatol Rep. 2020;22(6):24. doi:10.1007/s11926-020-00891-x
   PubMed Web of Science ®Google Scholar
• Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566–2573. doi:10.1111/jdv.16568
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi:10.1007/s00403-006-0703-z
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–703. doi:10.1001/archdermatol.2009.94
   PubMedGoogle Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Martin G, Young M, Aldredge L. Recommendations for initiating systemic therapy in patients with psoriasis. J Clin Aesthet Dermatol. 2019;12(4):13–26.
   PubMedGoogle Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790. doi:10.1111/jdv.14114
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26(6):502–506. doi:10.3109/09546634.2015.1034070
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176(5):1297–1307. doi:10.1111/bjd.15027
   PubMed Web of Science ®Google Scholar
• Esposito M, Gisondi P, Conti A, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31(5):863–869. doi:10.1111/jdv.14145
   PubMed Web of Science ®Google Scholar
• Mastorino L, Roccuzzo G, Dapavo P, et al. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population. Br J Dermatol. 2022;187(2):263–265. doi:10.1111/bjd.21048
   PubMed Web of Science ®Google Scholar
• Cariti C, Dapavo P, Mastorino L, et al. Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients. J Eur Acad Dermatol Venereol. 2022;36(3):e233–e235. doi:10.1111/jdv.17766
   PubMed Web of Science ®Google Scholar
• Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am J Manag Care. 2017;23(21 Suppl):S403–S416.
   PubMed Web of Science ®Google Scholar
• Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040–1047. doi:10.1111/j.1365-2133.2008.09023.x
   PubMed Web of Science ®Google Scholar
• Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–248. doi:10.1016/j.jaad.2015.05.001
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Isgrò V, Ientile V, Tari M, Trifirò G, Guarneri C. Are patients with psoriasis and psoriatic arthritis undertreated? A population-based study from Southern Italy. J Clin Med. 2021;10(15):3431. doi:10.3390/jcm10153431
   PubMed Web of Science ®Google Scholar
• Vanaclocha F, Crespo-Erchiga V, Jiménez-Puya R, et al. Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study. Actas Dermosifiliogr. 2015;106(1):35–43. doi:10.1016/j.ad.2014.06.003
   PubMedGoogle Scholar
• Lambert J, Ghislain PD, Lambert J, Cauwe B, Van den Enden M. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). J Dermatolog Treat. 2017;28(5):394–400. doi:10.1080/09546634.2016.1255304
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a Phase III study. Br J Dermatol. 2017;177(4):1014–1023. doi:10.1111/bjd.15666
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two Phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi:10.1016/S0140-6736(15
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Zagni E, Colombo D, Fiocchi M, et al. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):491–497. doi:10.1080/14737167.2020.1800456
   PubMed Web of Science ®Google Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the corrona psoriasis registry. Dermatol Ther. 2021;34(2):e14808. doi:10.1111/dth.14808
   PubMed Web of Science ®Google Scholar
• Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, Apol E, Hansen JB, Levin LÅ. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther. 2021;11(6):2107–2121. doi:10.1007/s13555-021-00616-7
   Web of Science ®Google Scholar
• Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis-A retrospective database study. Rheumatol Ther. 2021;8(1):483–497. doi:10.1007/s40744-021-00286-z
   PubMed Web of Science ®Google Scholar
• Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the effect of treatment persistence on the economic burden of moderate to severe psoriasis and/or psoriatic arthritis patients in the U.S. Department of defense population. J Manag Care Spec Pharm. 2018;24(7):654–663. doi:10.18553/jmcp.2018.24.7.654
   PubMed Web of Science ®Google Scholar
• Mastorino L, Castelli F, Stroppiana E, et al. Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients. J Eur Acad Dermatol Venereol. 2022;36(10):e838–e841. doi:10.1111/jdv.18314
   PubMed Web of Science ®Google Scholar